CVR Medical Announces Senior Management Appointment to Its QMS Team

Vancouver, British Columbia--(Newsfile Corp. - December 8, 2016) - CVR Medical Corp. (TSXV: CVM) (FSE: B3BN) (OTCQB: CRRVF) ("CVR Medical") announces the addition of Mr. Michael Rhodes to its executive management team. Mr. Rhodes has been named Vice President of Quality Systems.

With a decorated career spanning over twenty years in quality management positions, Mr. Rhodes brings a wealth of strategic knowledge and experience driving end-to-end quality objectives. Most recently the Global Head of Quality at HSBC and the former Chief Quality Officer at Motorola Solutions, his track record of appointments has preceded the successful implementations of systems that improved operational efficiency and decreased end-user reported problems at each company. His approach to developing relationships between provider and customer for technological products fits seamlessly with the nature of CVR's goal of bringing its "Carotid Stenotic Scan (CSS)" device to a large market of primary care clinics and non-specialist operators. Speaking on behalf of the Board of Directors, CVR Chief Operations Officer Tony Robinson states, "We are incredibly fortunate to have someone of Michael's character and capability joining our team. This is a huge boost for CVR, and we see it as a great sign of forward momentum."

Looking forward to his work with CVR Medical, Mr. Rhodes comments, "The first thing that drew me to this position was the product, the CSS, and what it can do. For me, the challenge will be to help get that product to exactly where we want it to be in terms of functionality and repeatability. Even when I was working with large corporations, I preferred to be hands-on, and the environment with CVR will be right in line with that."

For additional information on the organization, leadership, and current news please visit the newly launched company website www.CVRMed.com

About CVR Medical

CVR Medical is a company that is involved in an equal parts joint venture with CVR Global Inc. (the "Joint Venture"). The Joint Venture operates in the medical industry focused on the commercialization of a proprietary subsonic, infrasonic, and low frequency sound wave analysis technology and has patents to a diagnostic device designed to detect and measure carotid arterial stenosis. CVR Medical is managed by a proven technical team. CVR Medical trades on the TSX Venture Exchange under the symbol CVM.

ON BEHALF OF THE BOARD:
(signed) "Peter Bakema"
CEO, President & Director

For further information contact:
Brisco Capital Partners Corp.
Scott Koyich, President
Telephone: (403) 262-9888

This press release contains forward-looking information that involves various risks and uncertainties regarding future events related to the Joint Venture. Such statements are subject to risks and uncertainties that may cause actual results, performance or developments to differ materially from those contained in the statements and are not guarantees of future performance of the Company. No assurance can be given that any of the events anticipated by the forward-looking statements will occur or, if they do occur, what benefits the Company will obtain from them. These forward-looking statements reflect management's current views and are based on certain expectations, estimates and assumptions which may prove to be incorrect. A number of risks and uncertainties could cause our actual results to differ materially from those expressed or implied by the forward-looking statements, including: (1) a downturn in general economic conditions in North America and internationally, (2) the inherent uncertainties and speculative nature associated with commercialization of technology and the practice of medicine, (3) a change in health regulations, (4) any number of events or causes which may delay or cease commercialization and development of the Joint Venture, (5) the risk that the Company or the Joint Venture does not execute its business plan, (6) inability to retain key employees, (7) inability to finance operations and growth, and (8) other factors beyond the Company's control. These forward-looking statements are made as of the date of this news release and, except as required by law, the Company assumes no obligation to update these forward-looking statements, or to update the reasons why actual results differed from those projected in the forward-looking statements.

THE TSX VENTURE EXCHANGE INC. HAS NEITHER APPROVED NOR DISAPPROVED THE CONTENTS OF THIS PRESS RELEASE. NEITHER THE TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.